Assenagon Asset Management S.A. Ironwood Pharmaceuticals Inc Transaction History

Assenagon Asset Management S.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 25, 2023	BUY	$10.1 - $11.6 $51,055 - $58,638	5,055 Added 3.21%	162,559 $1.73 Million
Q1 2023 Apr 18, 2023	BUY	$10.37 - $12.56 $213,362 - $258,422	20,575 Added 15.03%	157,504 $1.66 Million
Q4 2022 Jan 12, 2023	SELL	$9.9 - $12.43 $105,999 - $133,088	-10,707 Reduced 7.25%	136,929 $1.7 Million
Q3 2022 Oct 27, 2022	BUY	$10.14 - $12.38 $116,883 - $142,704	11,527 Added 8.47%	147,636 $1.53 Million
Q2 2022 Jul 27, 2022	BUY	$11.05 - $12.72 $1.5 Million - $1.73 Million	136,109 New	136,109 $1.57 Million
Q1 2022 Apr 25, 2022	SELL	$10.61 - $12.88 $2.05 Million - $2.49 Million	-193,514 Closed	0 $0
Q4 2021 Feb 01, 2022	SELL	$10.86 - $13.95 $686,352 - $881,640	-63,200 Reduced 24.62%	193,514 $2.26 Million
Q3 2021 Oct 19, 2021	SELL	$11.92 - $13.92 $238 - $278	-20 Reduced 0.01%	256,714 $3.35 Million
Q1 2021 Apr 26, 2021	BUY	$9.04 - $11.86 $2.32 Million - $3.04 Million	256,734 New	256,734 $2.87 Million

238

162M

11.2M

9.1K

Ticker IRWD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 153,231,008
Market Cap $541M
Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.